Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of PJ009 in Healthy Adult Volunteers
NCT06523101Phase 1Completed
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Start
- Feb 2023
- Primary completion
- May 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in short bowel syndrome (SBS) comparing PJ009 Group with Placebo Group (2 arms). Primary endpoint: Treatment-related Adverse Events up to 18 days. Started Feb 2023; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT06523101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06523101.